CRISPR Therapeutics AG - Common Stock (CRSP)

Historical Holders from Q1 2016 to Q3 2025

Symbol
CRSP on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
90.4M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
72.2M
Holdings value
$4.68B
% of all portfolios
0.009%
Grand Portfolio weight change
+0%
Number of holders
429
Number of buys
214
Number of sells
-176
Average Value change %
+0%
Average buys %
+0.004%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CRISPR Therapeutics AG - Common Stock (CRSP)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 10.76% -9.08% $634M -$24.5M 9.79M -3.72% ARK Investment Management LLC 30 Sep 2025
Capital International Investors 7.4% $237M 6.33M Capital International Investors 31 Mar 2025
BlackRock, Inc. 6.9% $289M 5.93M BlackRock, Inc. 30 Jun 2025
ORBIS INVESTMENT MANAGEMENT LTD 5.5% $322M 4.97M ORBIS INVESTMENT MANAGEMENT LTD 30 Sep 2025

Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 72.2M $4.68B +$28.3M $64.81 429
2025 Q2 72.3M $3.52B +$429M $48.64 426
2025 Q1 64.1M $2.18B -$16.8M $34.03 388
2024 Q4 64.4M $2.54B +$180M $39.36 398
2024 Q3 59.8M $2.81B +$6.5M $46.98 407
2024 Q2 59.5M $3.21B +$50M $54.01 439
2024 Q1 57.3M $3.9B +$217M $68.16 469
2023 Q4 55.5M $3.48B +$42.6M $62.60 465
2023 Q3 55M $2.5B -$1.9M $45.39 400
2023 Q2 54.7M $3.07B -$80.9M $56.14 409
2023 Q1 56.2M $2.54B +$38.8M $45.23 375
2022 Q4 55.5M $2.26B -$74.8M $40.65 386
2022 Q3 56.7M $3.7B -$78.7M $65.35 410
2022 Q2 55.5M $3.34B +$272M $60.77 404
2022 Q1 49.5M $3.11B +$484M $62.77 415
2021 Q4 42.9M $3.25B +$73M $75.78 425
2021 Q3 40.4M $4.52B -$41.1M $111.93 458
2021 Q2 40.5M $6.56B -$153M $161.89 484
2021 Q1 42.6M $5.2B -$577M $121.85 431
2020 Q4 47.2M $7.22B +$35.3M $153.11 397
2020 Q3 47.9M $4B +$723M $83.64 300
2020 Q2 38.3M $2.81B +$279M $73.49 263
2020 Q1 35.5M $1.51B +$153M $42.41 244
2019 Q4 31.5M $1.92B +$255M $60.90 248
2019 Q3 27.5M $1.13B -$8.3M $40.99 176
2019 Q2 27.4M $1.29B +$108M $47.10 176
2019 Q1 26M $929M +$146M $35.72 163
2018 Q4 22.1M $631M -$57.8M $28.57 151
2018 Q3 22.9M $1.01B +$177M $44.35 171
2018 Q2 18.5M $1.09B -$651K $58.76 171
2018 Q1 18.7M $855M +$304M $45.71 132
2017 Q4 12.5M $293M +$61.8M $23.48 82
2017 Q3 10.1M $180M +$6.18M $17.87 61
2017 Q2 9.69M $155M -$4.33M $16.02 36
2017 Q1 9.69M $211M -$2.61M $21.77 36
2016 Q4 9.83M $198M +$198M $20.26 26
2016 Q2 0 $0 -$1K 0
2016 Q1 40 $1K $25.00 1